Pathology: es-BC - TNBC - NA - all population; es-BC - TNBC - NA - PDL1 positive;
| es-BC - TNBC - NA - all population | es-BC - TNBC - NA - PDL1 positive | |||||
| NeoTRIPaPDLA, 0 | IMpassion-031 (all population), 2020 | GeparNuevo, 2019 | KEYNOTE-522, 2020 | IMpassion-031 (PDL1>1%), 2020 | ||
| atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide | 2 | T1 | T1 | |||
| atezolizumab plus carboplatin plus nab-paclitaxel | 1 | T1 | ||||
| pembrolizumab alone | 1 | T1 | ||||
| durvalumab alone | 1 | T1 | ||||
| carboplatin plus nab-paclitaxel | 0 | T0 | ||||
| placebo plus SoC | 0 | T0 | T0 | |||
| placebo | 0 | T0 | T0 | |||